SARASOTA, FL -- (MARKET WIRE) -- September 27, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced the results of a recently completed market research study by the Diagnostics division of the Company’s Pharmaceuticals subsidiary which showed a large potential market for DNA tests that would better predict which patients are prone to Post Operative Nausea and Vomiting (PONV).
